Revolutionizing TUDCA Production: How Engineered Bacillus subtilis Unlocks a Cost-Effective Bear Bile Alternative

Introduction

Bear bile has been used in traditional Chinese medicine for centuries, prized for its liver-protective and anti-inflammatory properties. Its key therapeutic compound, tauroursodeoxycholic acid (TUDCA), is highly sought after in pharmaceuticals. However, reliance on bear bile raises ethical, environmental, and sustainability concerns.

A breakthrough study now shows how engineered Bacillus subtilis, a safe and widely used microbe, can produce high levels of TUDCA from taurochenodeoxycholic acid (TCDCA) found in inexpensive chicken bile powder—providing a scalable, cost-effective, and cruelty-free solution.

Engineering Microbial Cell Factories for TUDCA

Researchers constructed a two-step enzymatic pathway in B. subtilis using:

7α- and 7β-hydroxysteroid dehydrogenases (HSDHs): Key enzymes converting TCDCA to TUDCA.
Ribosome Binding Site (RBS) Optimization: Enhanced gene expression for higher enzyme activity.
NAD(P)H Cofactor Regeneration via Glucose Dehydrogenase (GDH): Ensured sufficient reducing power for the reaction, boosting TUDCA yield and stability.

The result? A whole-cell biotransformation system capable of producing over 15 g/L of TUDCA in just 15 hours—a massive improvement over previous methods.

Key Findings

High-Yield Production:
- Engineered strains A2-2 and A2-2-5 produced up to 15.10 g/L and 14.33 g/L of TUDCA, respectively.
Byproduct Reduction:
- GDH overexpression minimized unwanted intermediate buildup, making the process cleaner and more efficient.
Scalable and Sustainable:
- The process used inexpensive chicken bile powder as a starting material, replacing controversial bear bile sources.
Genetic Optimization Works:
- RBS strength correlated directly with TUDCA yields, confirming the power of synthetic biology tools in metabolic engineering.

Implications for Medicine and Sustainability

This research provides a practical route for large-scale, animal-free TUDCA production, paving the way for:

Pharmaceutical-grade TUDCA manufacturing for liver and neurodegenerative disease treatments.
Sustainable bioprocesses reducing reliance on endangered wildlife resources.
Cost-effective nutraceuticals with consistent quality and purity.

Conclusion

The engineering of Bacillus subtilis for TUDCA production marks a turning point in biotechnology—uniting synthetic biology, metabolic engineering, and sustainable practices to deliver high-value pharmaceuticals ethically and efficiently.

As this platform advances, we may soon see a future where medicine no longer depends on wildlife resources, making therapies both eco-friendly and affordable.

Reference

Jin, L., Niu, T., Wang, R., Yang, L., Zhao, S., & Wang, Z. (2025). High-level production of Tauroursodeoxycholic acid from Taurochenodeoxycholic acid in engineered Bacillus subtilis via whole-cell biotransformation. World Journal of Microbiology and Biotechnology, 41(10), 334. https://doi.org/10.1007/s11274-025-04549-7